EUCTR2012-005328-14-DK进行中(未招募)不适用
Effect of Sativex on neuropathic pain and spasticity following spinal cord injury
Spinal Cord Injury Centre of Western Denmark0 个研究点开始时间: 2013年4月16日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Neuropathic pain and / or spasticity after spinal cord injury / disease duration of at least 3 months, spinal cord injury must be at least 6 months prior to enrollment. The average intensity of the pain, respectively. spasticity measured on a numerical rating scale (NRS) (0-10) must be at least 4 in the baseline period (1 week). Age 18 years. Given informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •History of stroke or cerebral contusion or other cerebral injury with significant sequelae.
- •Patients who can’t cooperate or unable to complete the project due to lack of understanding of Danish
- •Pregnant or lactating women. Woman and men (or their partners) must use contraceptives during and three months after the trial has ended.
- •Known allergy to cannabinoids (THC / CBD) or excipients.
- •Previous or current schizophrenia, psychosis or other serious psychiatric disorder other than depression in the patient or immediate family.
- •Concomitant severe pain that can’t be distinguished from the neuropathic pain associated with spinal cord injury
- •Terminal illness or patients inappropriate for placebo.
- •Planned surgery, anesthesia or travel abroad during the trial.
- •History of severe cardiovascular disease, treatment with digoxin, poorly controlled hypertension, epilepsy or history of seizures
- •Significant impairment of liver or kidney.
- •There should not be use of cannabinoids 3 months before the study or during the study.
- •Abuse of cannabinoids, alcohol or medication. Patients who are in Antabus treatment should be excluded from the study due to interaction risk because Sativex contains alcohol.
研究者
相似试验
已完成
3 期
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple SclerosisMultiple SclerosisNCT01599234Jazz Pharmaceuticals337
进行中(未招募)
不适用
A study of Sativex for pain Relief and appetite stimulation in Patients with advanced malignancy. Phase IIadvanced malignant cancerMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001739-21-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
已完成
不适用
Resistant MS Spasticity Treatment with Sativex and DrivingMultiple sclerosisMS SpasticityG35DRKS00004877Almirall S.A.33
已完成
3 期
A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 YearsCerebral PalsyNCT01898520Jazz Pharmaceuticals72
已完成
3 期
A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple SclerosisNeuropathic PainMultiple SclerosisNCT01604265Jazz Pharmaceuticals66
